SPECIAL NOTICE
Q -- Collection of study document and pathology slides for AsiaLymph study in Taiwan
- Notice Date
- 6/10/2019
- Notice Type
- Synopsis
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- 9609 Medical Center Drive Rockville MD 20850
- ZIP Code
- 20850
- Solicitation Number
- 75N91019Q00082
- Response Due
- 6/19/2019
- Point of Contact
- Miguel Diaz, Contracting Officer, Phone 2402765439
- E-Mail Address
-
miguel.diaz@nih.gov
- Small Business Set-Aside
- N/A
- Description
- National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure, on a sole source basis, collection of missing documents and pathology slides from the AsiaLymph study in Taiwan from the University of Chicago at 5841 South Maryland Avenue, Chicago, IL 60637.. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(1)(i) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541990 and the business size standard is $15.0M.. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm and extend these observations has become limited in Western populations, due to the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium between key candidate genetic loci. Therefore, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. To this end, the National Cancer Institute is conducting a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph). The major postulated risk factors for evaluation in this study are chemical exposures, genetic susceptibility, and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should confirm and extend previous findings and yield novel insights into the causes of lymphoma in both Asia and the West. One of the study sites for the AsiaLymph study is Taiwan, which completed all enrollment and field activities for the study by 2016. To ensure the high quality and completion of this study, the National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) requires collection of missing documents and pathology slides from the previously enrolled subjects in Taiwan study center as well as preparation for shipment blood samples that were previously collected.. The purpose of this procurement is to support collection of missing pathology reports, medical records, scanning of study forms, requested pathology slides from subjects enrolled at the five Taiwanese hospitals participated in AsiaLymph study (Dalin Tzu Chi General Hospital, China Medical University Hospital, Kaohsiung Chang Gung Memorial Hospital, National Cheng Kung University Hospital, and Chi-mei Medical Center Hospital), and preparation for shipment samples to NCI.. The unique qualification of the University of Chicago Department of Health Studies is managing the ASiaLymph study in Taiwan. The University of Chicago has collaborated on epidemiological studies in Taiwan, specifically with the five Taiwanese hospitals that participated in the AsiaLymph study and is uniquely qualified to collect the missing documents and pathology slides from subjects who were previously enrolled in the Taiwan study center. For the aforementioned reasons, the University of Chicago is the only known source that can fulfill the requirements of this study.. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 12:00 PM ET, on June 19, 2019. All responses and questions must be via email to Miguel Diaz, Contracting Officer at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: 75N91019Q00082 on all correspondence. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (10-JUN-2019); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/HHS/NIH/RCB/75N91019Q00082/listing.html)
- Record
- SN05336057-F 20190612/190610230023 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |